DCT

5:26-cv-00147

Outplay Inc v. Summit Animal Health LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 5:26-cv-00147, M.D. Fla., 02/25/2026
  • Venue Allegations: Venue is alleged to be proper as Defendants maintain a principal place of business in the Middle District of Florida and have committed the alleged acts of infringement within the district.
  • Core Dispute: Plaintiff alleges that Defendants’ topical muscle relief gels for equine and human use infringe a patent related to a topical composition containing a carnosine-magnesium complex.
  • Technical Context: The technology lies in the field of sports performance supplements, specifically transdermal delivery systems for performance-enhancing compounds intended to reduce muscle fatigue and aid recovery.
  • Key Procedural History: The complaint alleges that principals of the Defendants became aware of Plaintiff's patented and commercially successful "Velocity" product, arranged for it to be reverse-engineered, and subsequently launched "copycat" products. These allegations form the basis for a claim of willful infringement.

Case Timeline

Date Event
2016-02-22 '868 Patent Priority Date
2018-01-01 Plaintiff's LactiGo product launched
2020-01-01 Plaintiff's Velocity product launched
2021-01-01 Defendant Summit founded
2021-04-13 '868 Patent Issued
2022-05-01 Alleged phone call regarding reverse-engineering of Plaintiff's product
2025-01-01 Defendant Bode founded
2026-02-25 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,973,868 - “Composition For Topical Use Based on a Carnosine-Magnesium Complex,” Issued April 13, 2021 (’868 Patent)

The Invention Explained

  • Problem Addressed: The patent describes the difficulty of delivering hydrophilic (water-soluble) molecules like carnosine through the skin’s protective outer layer, the stratum corneum, which is lipophilic (fat-loving) in nature (’868 Patent, col. 4:1-5). Carnosine itself is known to buffer lactic acid in muscle tissue, but an effective topical delivery method was needed (’868 Patent, col. 3:1-5).
  • The Patented Solution: The invention is a topical composition that complexes carnosine with magnesium ions. The patent asserts that this "carnosine-magnesium complex" facilitates the delivery of carnosine through the skin to the underlying skeletal muscle tissue, thereby improving physical performance (’868 Patent, abstract; ’868 Patent, col. 4:60-65). The inventors claim the unexpected discovery that coordinating magnesium to carnosine "produces a significant increase in the carnosine level in the lower skin layer following application to the skin" (’868 Patent, col. 3:21-26).
  • Technical Importance: The technology purports to offer a non-invasive method for enhancing athletic performance and recovery by delivering a key buffering agent directly to the site of action, bypassing the digestive system and potential degradation associated with oral supplements.

Key Claims at a Glance

  • The complaint asserts infringement of at least independent Claim 1 (’868 Patent, col. 17:11-20). The complaint alleges infringement of "one or more claims" of the patent (Compl. ¶64).
  • Independent Claim 1 Elements:
    • A topical composition
    • comprising a physiologically active amount of a carnosine-magnesium complex,
    • wherein the physiologically active amount of the carnosine-magnesium complex represents a quantity of the carnosine-magnesium complex of from 0.5 to 5 wt % of the topical composition
    • for delivering carnosine to skeletal muscle tissue.

III. The Accused Instrumentality

Product Identification

  • The accused products are "Summit Animal Health's Muscle Relief Gel" and "Bode Health's Muscle Recovery Gel" (Compl. ¶9). The complaint alleges that the two products are the same or comprise the same infringing formulation (Compl. ¶15; Compl. ¶58).

Functionality and Market Context

  • The Summit product is a topical gel marketed for muscle relief and recovery in horses, while the Bode product is marketed for similar purposes in humans (Compl. ¶35; Compl. ¶50). Both products are advertised as containing an "advanced 3% L-Carnosine formula" that is "paired with magnesium sulfate" (Compl. ¶38; Compl. ¶53). The complaint presents evidence that the Bode product line is marketed to humans directly from the Summit Animal Health website, suggesting a coordinated business strategy (Compl. ¶57). A screenshot from the Summit website shows a banner that reads "Shop human products at Bode HEALTH" (Compl. ¶57, p. 22). The complaint positions the accused products as "knock-off" or "copycat" versions of Plaintiff's commercially successful "Velocity" product (Compl. ¶41).

IV. Analysis of Infringement Allegations

’868 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical composition... The accused product is a gel designed for topical application to the skin of a horse. ¶65 col. 5:5-11
comprising a physiologically active amount of a carnosine-magnesium complex, The accused product is advertised as containing "L-Carnosine" and "Magnesium Sulfate," which the complaint alleges are "active" ingredients that form the claimed complex. ¶65 col. 2:60-65
wherein the physiologically active amount of the carnosine-magnesium complex represents a quantity of the carnosine-magnesium complex of from 0.5 to 5 wt % of the topical composition... The accused product is advertised as containing a "3% L-Carnosine formula," which falls within the claimed 0.5 to 5 wt % range. ¶65 col. 5:17-27
for delivering carnosine to skeletal muscle tissue. The accused product is advertised as a muscle relief gel that "soothes sore muscles" and "reduces inflammation and swelling." ¶65 col. 17:18-20

Identified Points of Contention

  • Chemical Identity Question: A primary point of contention may be whether the simple mixture of "L-Carnosine" and "Magnesium Sulfate" in an aqueous gel, as alleged in the complaint (Compl. ¶65, p. 27), necessarily forms the specific "carnosine-magnesium complex" required by the claims. The defense may argue their product is a mere mixture, not the claimed complex. A screenshot in the complaint shows the advertised "Key Ingredients" of L-Carnosine and Magnesium Sulfate (Compl. ¶38, p. 14).
  • Quantitative Scope Question: The infringement allegation relies on the advertised "3% L-Carnosine formula" corresponding to the claimed "3 wt % of the...carnosine-magnesium complex" (Compl. ¶65, p. 28). The defense could argue that the 3% figure refers only to the L-carnosine component, not the entire complex. If true, the weight percentage of the full complex could fall outside the claimed 0.5-5% range, raising a question of literal infringement. A side-by-side comparison of the Summit and Bode websites shows both advertise the "3% L-Carnosine formula" (Compl. ¶53, p. 21).

V. Key Claim Terms for Construction

The Term: "carnosine-magnesium complex"

  • Context and Importance: The existence of this specific "complex" is the lynchpin of the infringement allegation. The dispute may turn on whether combining the base ingredients as advertised in the accused products is sufficient to create the claimed chemical entity. Practitioners may focus on this term because the defendants could argue their product is a simple mixture that does not meet the structural or chemical properties of the claimed "complex."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification suggests the complex forms readily, stating it "can be prepared by combining a magnesium salt, an aqueous solution, and carnosine" and that it forms "almost instantaneously" at room temperature (’868 Patent, col. 8:20-37). This may support an argument that any formulation containing these ingredients in water inherently contains the claimed complex.
    • Evidence for a Narrower Interpretation: Claim 2, which depends from Claim 1, recites a specific chemical formula and structure for the complex. The specification also includes a chemical diagram of this structure (’868 Patent, col. 2:5-15; ’868 Patent, claim 2). A defendant may argue that the term "carnosine-magnesium complex" in Claim 1 should be construed as being limited to this specific, depicted chemical structure, which might not be formed in their product.

The Term: "a quantity of the carnosine-magnesium complex of from 0.5 to 5 wt %"

  • Context and Importance: This limitation defines the concentration range required for infringement. The interpretation is critical because the accused products are advertised based on the concentration of "L-Carnosine," not the "complex."
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A plaintiff might argue that in the context of the patent, which teaches combining the ingredients, one of ordinary skill would understand that the weight percentage is based on the primary active ingredient (carnosine) used to form the complex.
    • Evidence for a Narrower Interpretation: A defendant is likely to argue for a plain meaning: the claim requires the weight of the entire complex (carnosine plus magnesium) to be between 0.5 and 5% of the total composition's weight. They may argue that the plaintiff has not shown this to be the case for the accused products, even if they contain 3% carnosine by weight.

VI. Other Allegations

Indirect Infringement

  • The complaint alleges two theories of inducement. First, that Defendants induce end-users to infringe by providing instructions on how to topically apply the products for their intended purpose (Compl. ¶66). Second, that Defendants, acting in concert, induce a common manufacturer to directly infringe by ordering and purchasing a raw product that meets the claim elements (Compl. ¶61; Compl. ¶67).

Willful Infringement

  • Willfulness is alleged based on pre-suit knowledge of the ’868 Patent. The complaint constructs a detailed narrative alleging that an equestrian athlete, after using and liking Plaintiff's "Velocity" product, arranged for it to be "reverse engineered" in May 2022 to create a "copycat product" (Compl. ¶¶41-42). This copycat product, initially called "Prime Equine Emulgel," was allegedly later distributed through Defendant Summit (Compl. ¶43). The complaint includes a screenshot from Summit's Instagram account advertising this initial product (Compl. ¶43, p. 16). The complaint further alleges that Plaintiff’s products were marked with the patent number, providing constructive notice (Compl. ¶47).

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of chemical identity: does the combination of L-carnosine and magnesium sulfate as formulated in the accused gels create the specific "carnosine-magnesium complex" claimed in the ’868 Patent, or is it a simple mixture falling outside the claim scope?
  • A second key issue will be one of quantitative analysis: does the advertised "3% L-Carnosine" content of the accused products mean that the "carnosine-magnesium complex" itself comprises 3% of the total product weight, as required by Claim 1, or is the actual weight percentage of the full complex different, potentially placing the products outside the claimed range?
  • Finally, the case may turn on the strength of the willfulness narrative: the plaintiff has presented detailed factual allegations of intentional copying, including reverse engineering. The extent to which these allegations can be substantiated through discovery will be central to the claim for enhanced damages.
Loading Complaint